Semaglutide
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes..., Reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes..., Reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular...
Boxed warning
- WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . • OZEMPIC is contraindicated in patients with a personal or ... (see full label)
Indications
- Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes...
- Reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes...
- Reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular...
Adult dosing
- initial: dose: 0.25; unit: mg; route: SC; interval: once weekly for 4 weeks; fixed: true; labelExcerpt: Initiate OZEMPIC with a dosage of 0.25 mg injected subcutaneously once weekly for 4 weeks.
- maintenance: dose: 0.5; unit: mg; route: SC; interval: once weekly; fixed: true; labelExcerpt: The recommended maintenance dosage is 0.5 mg, 1 mg, or 2 mg, injected subcutaneously once weekly, based on glycemic control.
Pediatric dosing
- Consult pharmacy/current label
Renal adjustment
- Consult pharmacy/current label
Hepatic adjustment
- Consult pharmacy/current label
Contraindications
- Personal or family history of MTC
- Patients with MEN 2
- Serious hypersensitivity to semaglutide
Clinical pearls
- Administer subcutaneously once weekly in the abdomen, thigh, or upper arm.
- Discontinue at least 2 months before a planned pregnancy.
- Monitor for symptoms of acute pancreatitis (e.g., persistent severe abdominal pain).
- Never share pens between patients due to risk of blood-borne pathogens.
Source and review
- DailyMed label (semaglutide, Ozempic), Set ID 42bdd912-2393-44c4-b7e0-47672ca28991, effective 2026-07-30. Last reviewed: 2026-11-11
RotationRx · Drugs · Scores · Protocols · Diagnoses · Specialties